355 related articles for article (PubMed ID: 21284696)
21. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
de Silva VA; Suraweera C; Ratnatunga SS; Dayabandara M; Wanniarachchi N; Hanwella R
BMC Psychiatry; 2016 Oct; 16(1):341. PubMed ID: 27716110
[TBL] [Abstract][Full Text] [Related]
22. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.
Milano W; Grillo F; Del Mastro A; De Rosa M; Sanseverino B; Petrella C; Capasso A
Adv Ther; 2007; 24(1):123-34. PubMed ID: 17526469
[TBL] [Abstract][Full Text] [Related]
23. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder.
Detke HC; DelBello MP; Landry J; Hoffmann VP; Heinloth A; Dittmann RW
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):922-934. PubMed ID: 27676420
[TBL] [Abstract][Full Text] [Related]
24. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.
Ellul P; Delorme R; Cortese S
CNS Drugs; 2018 Dec; 32(12):1103-1112. PubMed ID: 30238318
[TBL] [Abstract][Full Text] [Related]
25. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
Bushe CJ; Bradley AJ; Doshi S; Karagianis J
Int J Clin Pract; 2009 Dec; 63(12):1743-61. PubMed ID: 19840151
[TBL] [Abstract][Full Text] [Related]
26. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
27. Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Anagnostou E; Aman MG; Handen BL; Sanders KB; Shui A; Hollway JA; Brian J; Arnold LE; Capano L; Hellings JA; Butter E; Mankad D; Tumuluru R; Kettel J; Newsom CR; Hadjiyannakis S; Peleg N; Odrobina D; McAuliffe-Bellin S; Zakroysky P; Marler S; Wagner A; Wong T; Macklin EA; Veenstra-VanderWeele J
JAMA Psychiatry; 2016 Sep; 73(9):928-37. PubMed ID: 27556593
[TBL] [Abstract][Full Text] [Related]
28. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of metformin to limit weight-gain with atypical antipsychotics.
Lee YJ; Jeong JH
J Clin Pharm Ther; 2011 Oct; 36(5):537-45. PubMed ID: 21418264
[TBL] [Abstract][Full Text] [Related]
30. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
[TBL] [Abstract][Full Text] [Related]
31. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.
Björkhem-Bergman L; Asplund AB; Lindh JD
J Psychopharmacol; 2011 Mar; 25(3):299-305. PubMed ID: 20080925
[TBL] [Abstract][Full Text] [Related]
32. Antipsychotic-induced weight gain in patients with schizophrenia.
Venkatasubramanian G
JAMA; 2008 Apr; 299(16):1899; author reply 1899-900. PubMed ID: 18430906
[No Abstract] [Full Text] [Related]
33. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine for schizophrenia.
Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
Cochrane Database Syst Rev; 2003; (1):CD001359. PubMed ID: 12535408
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.
Maayan L; Vakhrusheva J; Correll CU
Neuropsychopharmacology; 2010 Jun; 35(7):1520-30. PubMed ID: 20336059
[TBL] [Abstract][Full Text] [Related]
36. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
[TBL] [Abstract][Full Text] [Related]
37. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Arman S; Sadramely MR; Nadi M; Koleini N
Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
[TBL] [Abstract][Full Text] [Related]
39. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
40. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
Narula PK; Rehan HS; Unni KE; Gupta N
Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
